LIFE Stock Forecast 2025-2026
Distance to LIFE Price Targets
LIFE Price Momentum
🤔 Considering aTyr Pharma (LIFE)?
Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.
Latest LIFE Stock Price Targets & Analyst Predictions
Based on our analysis of 9 Wall Street analysts, LIFE has a neutral consensus with a median price target of $22.00 (ranging from $16.00 to $35.00). The overall analyst rating is Strong Buy (8.0/10). Currently trading at $3.97, the median forecast implies a 454.2% upside. This outlook is supported by 1 Buy, 4 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Joseph Pantginis at HC Wainwright & Co., projecting a 781.6% upside. Conversely, the most conservative target is provided by Gregory Renza at RBC Capital, suggesting a 303.0% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
LIFE Analyst Ratings
LIFE Price Target Range
Latest LIFE Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for LIFE.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| May 14, 2024 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $35.00 |
| May 3, 2024 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $35.00 |
| May 3, 2024 | HC Wainwright& Co. | Buy | Reiterates | $0.00 | |
| Mar 15, 2024 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $35.00 |
| Mar 15, 2024 | RBC Capital | Gregory Renza | Outperform | Maintains | $16.00 |
| Feb 21, 2024 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $35.00 |
| Sep 21, 2023 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $35.00 |
| Sep 14, 2023 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $35.00 |
| Aug 10, 2023 | HC Wainwright & Co. | Buy | Reiterates | $0.00 | |
| Jul 21, 2023 | Piper Sandler | Overweight | Maintains | $0.00 | |
| Jul 5, 2023 | Oppenheimer | Hartaj Singh | Perform | Downgrade | $0.00 |
| May 23, 2023 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $35.00 |
| May 10, 2023 | RBC Capital | Gregory Renza | Outperform | Reiterates | $19.00 |
| Apr 11, 2023 | Piper Sandler | Edward Tenthoff | Overweight | Maintains | $13.00 |
| Mar 10, 2023 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $35.00 |
| Mar 10, 2023 | RBC Capital | Gregory Renza | Outperform | Reiterates | $19.00 |
| Mar 6, 2023 | Roth MKM | Kumaraguru Raja | Buy | Reinstates | $9.00 |
| Mar 2, 2023 | RBC Capital | Gregory Renza | Outperform | Maintains | $19.00 |
| Feb 7, 2023 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $35.00 |
| Aug 16, 2022 | Piper Sandler | Edward Tenthoff | Overweight | Maintains | $14.00 |
aTyr Pharma Inc (LIFE) Competitors
The following stocks are similar to aTyr Pharma based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
aTyr Pharma Inc (LIFE) Financial Data
aTyr Pharma Inc has a market capitalization of $131.12M with a P/E ratio of -4.2x. The company generates $588,000 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of -7,079.1% and return on equity of -55.6%.
Valuation Metrics
Growth & Margins
Financial Health
🔥 Want More High-Potential Stock Ideas?
Join 5,000+ investors getting our research on stocks with massive upside potential.
aTyr Pharma Inc (LIFE) Business Model
About aTyr Pharma Inc
Develops biotherapeutics targeting immunological pathways.
aTyr Pharma focuses on discovering and developing innovative medicines that target novel immunological pathways. The company generates revenue through the development of its therapeutic candidates, which are in various stages of clinical trials, and through collaboration and licensing agreements, such as its partnership with Kyorin Pharmaceutical for efzofitimod in Japan.
The company's lead candidate, efzofitimod, is currently in Phase III trials for pulmonary sarcoidosis and Phase 1b/2a for other interstitial lung diseases. Additionally, aTyr Pharma is working on other candidates, such as ATYR0101 and ATYR0750, aimed at treating fibrosis and liver disorders, respectively. Founded in 2005 and based in San Diego, California, the company is well-positioned in the biotherapeutics sector.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
56
CEO
Dr. Sanjay S. Shukla M.D., M.S.
Country
United States
IPO Year
2015
Website
www.atyrpharma.comaTyr Pharma Inc (LIFE) Latest News & Analysis
Investors can potentially achieve significant gains in the stock market by investing in stocks priced at $2 that may increase tenfold by 2025.
Identifying low-cost stocks with high growth potential can attract investors seeking significant returns, highlighting opportunities in the market for strategic buying.
aTyr Pharma, Inc. will change its Nasdaq ticker symbol from "LIFE" to "ATYR" effective June 5, 2024. The company focuses on developing medicines from its tRNA synthetase platform.
The ticker symbol change from "LIFE" to "ATYR" may enhance brand recognition and investor interest, potentially impacting trading volume and stock performance.
aTyr Pharma granted nonstatutory stock options for 9,400 shares at $1.86 each to new employees, in line with Nasdaq rules and its 2022 Inducement Plan.
The stock options granted to new employees indicate aTyr's commitment to attracting talent, which can enhance innovation and productivity, potentially impacting future growth and stock performance.
aTyr Pharma will present data on its lead candidate, efzofitimod, at the ATS 2024 Conference, highlighting its anti-inflammatory effects in pulmonary sarcoidosis.
The presentation of efzofitimod data may signal progress in treating pulmonary sarcoidosis, potentially boosting aTyr Pharma's stock value and investor confidence in its pipeline.
aTyr Pharma Announces Second Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT™ Study in Pulmonary Sarcoidosis
10 months agoThe DSMB has recommended continuing the study of efzofitimod without changes, indicating a favorable safety profile for the treatment.
The DSMB's recommendation indicates confidence in efzofitimod's safety, potentially boosting investor sentiment and stock performance for the company developing the drug.
Enrollment for the Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis is projected to finish by Q2 2024. The company reported $87.7 million in cash and investments at Q1 2024.
Completion of the Phase 3 study and strong cash position signal potential for efzofitimod's market viability and financial stability, influencing investment confidence.
Frequently Asked Questions About LIFE Stock
What is aTyr Pharma Inc's (LIFE) stock forecast for 2025?
Based on our analysis of 9 Wall Street analysts, aTyr Pharma Inc (LIFE) has a median price target of $22.00. The highest price target is $35.00 and the lowest is $16.00.
Is LIFE stock a good investment in 2025?
According to current analyst ratings, LIFE has 1 Buy ratings, 4 Hold ratings, and 0 Sell ratings. The stock is currently trading at $3.97. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for LIFE stock?
Wall Street analysts predict LIFE stock could reach $22.00 in the next 12 months. This represents a 454.2% increase from the current price of $3.97. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is aTyr Pharma Inc's business model?
aTyr Pharma focuses on discovering and developing innovative medicines that target novel immunological pathways. The company generates revenue through the development of its therapeutic candidates, which are in various stages of clinical trials, and through collaboration and licensing agreements, such as its partnership with Kyorin Pharmaceutical for efzofitimod in Japan.
What is the highest forecasted price for LIFE aTyr Pharma Inc?
The highest price target for LIFE is $35.00 from Joseph Pantginis at HC Wainwright & Co., which represents a 781.6% increase from the current price of $3.97.
What is the lowest forecasted price for LIFE aTyr Pharma Inc?
The lowest price target for LIFE is $16.00 from Gregory Renza at RBC Capital, which represents a 303.0% increase from the current price of $3.97.
What is the overall LIFE consensus from analysts for aTyr Pharma Inc?
The overall analyst consensus for LIFE is neutral. Out of 9 Wall Street analysts, 1 rate it as Buy, 4 as Hold, and 0 as Sell, with a median price target of $22.00.
How accurate are LIFE stock price projections?
Stock price projections, including those for aTyr Pharma Inc, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
